Artiva Biotherapeutics, Inc. 4

Director Elaine K. Sorg received an option award for 13,750 shares of Artiva Biotherapeutics, Inc. common stock at a $10.88 exercise price.

On September 8, 2026, director Elaine K. Sorg received a stock option award from Artiva Biotherapeutics, Inc. covering 13,750 shares of common stock at an exercise price of $10.88 per share, with the option vesting in full on the earlier of September 8, 2027 or the company’s 2027 annual stockholder meeting and expiring on September 7, 2036; following this grant, she beneficially owns 13,750 shares (or options equivalent) in the company, representing a routine director equity compensation award rather than an open‑market purchase or sale.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-385418

Alert Tier

5